J.P. Morgan Sticks to Its Buy Rating for Kiniksa Pharmaceuticals (KNSA)

J.P. Morgan analyst Anupam Rama maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA – Research Report) yesterday and set a price target of $40.00. The company’s shares closed yesterday at $21.48.

According to TipRanks, Rama is a 4-star analyst with an average return of 3.0% and a 45.95% success rate. Rama covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Neurocrine, and Travere Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kiniksa Pharmaceuticals with a $37.50 average price target, representing a 74.58% upside. In a report released on October 30, Evercore ISI also assigned a Buy rating to the stock with a $35.00 price target.

Based on Kiniksa Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $112.21 million and a GAAP net loss of $12.69 million. In comparison, last year the company earned a revenue of $67.05 million and had a GAAP net loss of $13.86 million

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Kiniksa Pharmaceuticals (KNSA) Company Description:

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.